Skip to Main Content

Tarsus Pharmaceuticals, Inc. Common Stock

TARS Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of TARS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
TARS Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
TARS Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
TARS Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by TARS's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

TARS Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
TARS Income Statement
TARS Balance Sheet
TARS Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Pharmaceutical compositions for demodex related blepharitis and eyelid crusting Mar. 25, 2025
  • Patent Title: Isoxazoline parasiticide formulations Feb. 04, 2025
  • Patent Title: Isoxazoline parasiticide formulations and methods for treating blepharitis Dec. 24, 2024
  • Patent Title: Ophthalmic compositions for treating ocular Sep. 12, 2023
  • Patent Title: Methods for treating ocular Jul. 04, 2023
  • Patent Title: Methods for treating demodex blepharitis using lotilaner formulations Jul. 04, 2023
  • Patent Title: Isoxazoline parasiticide formulations and methods for treating blepharitis Dec. 14, 2021
  • Patent Title: Methods for treating ocular demodex using isoxazoline parasiticide formulations Nov. 17, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
TARS News

Recent insights relating to TARS

WallStreetBets

Number of mentions of TARS in WallStreetBets Daily Discussion

CNBC Recommendations

Recent picks made for TARS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TARS

TARS Analyst Ratings

TARS Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
TARS Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $TARS stock a Buy, Sell, or Hold?

  • What is the price target for $TARS stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

TARS Top Shareholders
Shareholder
Shares Held
TARS Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $TARS stock?

  • Who owns the most shares of $TARS stock?

  • What funds own $TARS stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

TARS Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view TARS Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top